MRSA knee infection treated successfully with daptomycin after two failed prolonged high-dose courses of vancomycin

Infectious Diseases in Clinical Practice

Volumn 13, Issue 6, 2005, Pages 327-329

  Dretler, Robin ^a,b,d   Branch, Thomas ^b,c  

^a Infectious Disease Specialists of Atlanta ^*  (United States)

^b DeKalb Medical Center   (United States)

^c University Orthopedic Clinic   (United States)

^d Infectious Disease Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZATROPINE; CEFAZOLIN; CLOZAPINE; DAPTOMYCIN; HYDROCODONE; PAROXETINE; RIFAMPICIN; VANCOMYCIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; JOINT EFFUSION; KNEE ARTHROPLASTY; MENTAL DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; SCHIZOPHRENIA; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 28044438669     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000175817.71485.f7     Document Type: Article

References (20)

1. Bernard L, Hoffmeyer P, Assal M, et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother. February 2004;53(2):127-129.
2. Eshkenazi AU, Garti A, Tamir L, et al. Serum and synovial vancomycin concentrations following prophylactic administration in knee arthroplasty. Am J Knee Surg. 2001;14(4):221-223.
3. Mini E, Grassi F, Cherubino P, et al. Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. J Chemother. November 2001;13 Spec No 1(1):73-79.
4. van de Belt H, Neut D, Schenk W, et al. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthop Scand. December 2001;72(6):557-571.
5. Center for Disease Control and Prevention, Department of Health and Human Services. Proportion of S. aureus nosocomial infections resistant to oxacillin (MRSA) among intensive care unit patients, 1989-2003. 2003. Ref Type: Generic.
6. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. August 2001;48(Suppl A):S9-S14.
7. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol. 2002;56:657-675.
8. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. June 2004;42(6):2398-2402.
9. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother. April 2004;53(4):669-674.
10. Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother. March 2004;48(3):1007-1011.
11. Restrepo MI, Velez JA, McElmeel ML, et al. Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. September 2003;47(9):2974-2977.
12. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structured infections. Clin Infect Dis. June 15, 2004;38(12):1673-1681.
13. Cubicin® (Daptomycin for Injection) Prescribing Information. Lexington, MA: Cubist Pharmaceuticals; September 2003.
14. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. May 1989;33(5):689-692.
15. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. April 2003;47(4):1318-1323.
16. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. September 2003;17(3):479-501.
17. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. August 2003;47(8):2538-2544.
18. Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother. April 2000;44(4):1062-1066.
19. Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother. September 2003;47(9):3012-3014.
20. Levison ME. Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects. Infect Dis Clin North Am. September 1995;9(3):483-495.